Dr. Beck has contributed to the R&D of anticancer mAbs (dalotuzumab/IGF-1R with Merck, h224G11/cMet with Abbott, h515H7/CXCR4, h6F4/JAM-A), vaccines and peptides. He is inventor on 16 patents and author of more than 90 publications (editorials, features, research papers, invited reviews and meeting reports). He acts as associate editor of mAbs (www.landesbioscience.com) and as invited guest editor or contributor for special issues on mAbs (Nature Rev Immunol, Curr Pharm Biotech, Medecine/ Sciences, Analytical Chemistry, Exp Op Drug Discov and Meth Mol Biol). He has contributed to more than 140 scientific meetings as chairman, invited keynote speaker, panelist, moderator, advisor, and/or organizer. He is regularly interviewed on biosimilars, biobetters, next generation antibodies, antibody drug conjugates, bispecifics, Fc-fusion proteins and peptides and alternative protein scaffolds (New York Times, Nature Biotech, Nature Rev Drug Discovery, Analytical Chemistry, Chemistry World, LEEM magazine). He is also frequently invited to boards of experts by WHO, EMA, European Commission, funding agencies (Czech, Dutch, Ontario, New Zealand), French valorization agencies (ANR, INCa, INSERM, Oséo, Labex, LEEM) and bio-clusters (Alsace Biovalley, Cancer BioSante, CLARA, Genopole, LyonBiopole, Medicen).
Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October